| Autor: |
Hamid OA; Nemours Children's Health, Orlando, Florida., Hester DM; Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas., Matesanz SE; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Wright S; Children's National Hospital, Washington, District of Columbia., Batley KY; UT Southwestern Medical Center, Dallas, Texas., Proud CM; Children's Hospital of The King's Daughters, Norfolk, Virginia., Veerapandiyan A; Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address: aveerapandiyan@uams.edu. |
| Abstrakt: |
Competing Interests: Declaration of competing interest O.A.H. has received compensation for ad hoc advisory boards with PTC therapeutics, Sarepta, Catalyst, and Percheron and speaker's bureau for Biogen and Genentech. S.E.M. has received compensation for ad hoc advisory boards/consulting for Sarepta, Novartis, and Atamyo Therapeutics. S.W. has received compensation for advisory boards for Sarepta. K.Y.B. has received compensation for consulting/advisory role with Biogen, UCB, Reata Pharmaceuticals, Pfizer, Catalyst Pharmaceuticals, and MyTomorrows. C.M.P. has received honoraria for advisory board participation from Biogen, Novartis, Roche, and Sarepta and speaker's fees from Biogen and Novartis. A.V. has received compensation for ad hoc advisory boards/consulting activity with Biogen, Novartis, AveXis, Sarepta, PTC, Scholar Rock, Fibrogen, AMO, Pfizer, Catalyst, Lupin, Entrada, MyTomorrows, Percheron, and Italfarmaco. |
Full Text from ScienceDirect